Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · IEX Real-Time Price · USD
7.00
-0.04 (-0.64%)
Jul 22, 2024, 10:21 AM EDT - Market open
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 100 employees as of December 31, 2023. The number of employees increased by 78 or 354.55% compared to the previous year.
Employees
100
Change (1Y)
78
Growth (1Y)
354.55%
Revenue / Employee
$89,130
Profits / Employee
-$807,370
Market Cap
296.94M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AngioDynamics | 815 |
Adaptimmune Therapeutics | 449 |
SOPHiA GENETICS | 430 |
Poseida Therapeutics | 330 |
Alimera Sciences | 159 |
Enanta Pharmaceuticals | 145 |
Atea Pharmaceuticals | 75 |
Opthea | 24 |
VRCA News
- 21 days ago - Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. - GlobeNewsWire
- 7 weeks ago - Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 - GlobeNewsWire
- 3 months ago - Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 months ago - Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA - GlobeNewsWire